Abstract
The carbohydrate antigen 3‐fucosyl‐N‐acetyl‐lactos‐amine (FAL) is expressed on human granulocytes and is detected by a monoclonal antibody B4.3. After neuraminidase treatment, this structure can also be detected on monocytes and on the cells of nearly all acute myeloid leukemia patients (38/39). It is then also present on the cells of a number of CALLA‐positive lymphatic leukemias (8/18), but not on T‐ALL and B‐ALL cells. On cells of patients with AUL, the antigen is then detected in many TdT+ cases, but not in TdT− cases. Copyright © 1984 Wiley‐Liss, Inc., A Wiley Company
| Original language | English |
|---|---|
| Pages (from-to) | 355-358 |
| Journal | International Journal of Cancer |
| Volume | 33 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1984 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Detection of the granulocyte‐specific antigen 3‐fucosyl‐N‐acetyl‐lactosamine on leukemic cells after neuraminidase treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver